

Xenpozyme

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	_ NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info:	g Provider
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info: 🗖 Same as Referring I	Provider 🗖 Same as Requesting Provider
Name:	NPI#:
Fax:	Phone:
	g limits in accordance with FDA-approved labeling, nd/or evidence-based practice guidelines.
Required Demographic Information:	

Patient Weight:	kg
Patient Height:	ст

Please indicate the place of service for the requested drug:

□ Ambulatory Surgical (POS Code 24)

□ Off Campus Outpatient Hospital (POS Code 19)

Home (POS Code 12)
On Campus Outpatient Hospital (POS Code 22)

Drug Information:

Strength/Measure	_ <i>Units</i> □ ml □ Gm □ mg □ ea □ Un
Directions(sig)	Route of administration
Dosing frequency	_

What is the ICD-10 code?

□ Office (POS Code 11)

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC PP Xenpozyme SGM 5560-A - 10/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com

Criteria Questions:

1. What is the diagnosis?

□ Acid sphingomyelinase deficiency (ASMD), Continue to 2

□ Other, please specify. _____, Continue to 2

2. Is the patient currently receiving treatment with the requested drug?

□ Yes, Continue to 3

□ No, Continue to 4

3. Has the patient demonstrated a response to therapy (e.g., improvement in lung function, reduction in spleen volume, reduction in liver volume, improvement in platelet count, improvement in linear growth progression)? *ACTION REQUIRED*: If yes, attach documentation (e.g., chart notes, lab results) of a response to therapy (e.g., improvement in lung function, reduction in spleen volume, reduction in liver volume, improvement in platelet count, improvement in linear growth progression).

D Yes, *No Further Questions*

D No, *No Further Questions*

4. Will the requested drug be used for the treatment of non-CNS manifestations of acid sphingomyelinase deficiency (ASMD)?

□ Yes, Continue to 5

□ No, *Continue to 5*

5. Was the diagnosis confirmed by a documented deficiency of acid sphingomyelinase as measured in peripheral leukocytes, cultured fibroblasts, or lymphocytes? *ACTION REQUIRED*: If yes, attach acid sphingomyelinase enzyme assay results supporting the diagnosis.

☐ Yes, No Further Questions
☐ No, Continue to 6

6. Was the diagnosis confirmed by genetic testing documenting a mutation in the sphingomyelin phosphodiesterase-1 (SMPD1) gene? *ACTION REQUIRED*: If yes, attach genetic testing results supporting the diagnosis.

Yes, No Further Questions
No, No Further Questions

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

Х

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC PP Xenpozyme SGM 5560-A - 10/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076 Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com